323 related articles for article (PubMed ID: 17690113)
1. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
[TBL] [Abstract][Full Text] [Related]
2. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
3. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC
Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125
[TBL] [Abstract][Full Text] [Related]
4. Familial gastric cancer and Li-Fraumeni syndrome.
Corso G; Pedrazzani C; Marrelli D; Pinto E; Roviello F
Eur J Cancer Care (Engl); 2010 May; 19(3):377-81. PubMed ID: 19674071
[TBL] [Abstract][Full Text] [Related]
5. Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses.
Fox JG; Sheppard BJ; Dangler CA; Whary MT; Ihrig M; Wang TC
Cancer Res; 2002 Feb; 62(3):696-702. PubMed ID: 11830522
[TBL] [Abstract][Full Text] [Related]
6. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
Wu CC; Shete S; Amos CI; Strong LC
Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
[TBL] [Abstract][Full Text] [Related]
7. Germline alterations in the CDH1 gene in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Ito H; Kasami M; Sasaki N; Shima H; Ikeda M; Tao H; Goto M; Ozawa T; Tsuneyoshi T; Tanioka F; Sugimura H
Cancer Sci; 2011 Oct; 102(10):1782-8. PubMed ID: 21777349
[TBL] [Abstract][Full Text] [Related]
8. A germ line mutation in exon 5 of the p53 gene in an extended cancer family.
Law JC; Strong LC; Chidambaram A; Ferrell RE
Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902
[TBL] [Abstract][Full Text] [Related]
9. Cancer risks from germ line tumor suppressor gene mutations.
Frebourg T; Malkin D; Friend S
Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
[TBL] [Abstract][Full Text] [Related]
10. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
11. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
12. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
13. Germ-line splicing mutation of the p53 gene in a cancer-prone family.
Warneford SG; Witton LJ; Townsend ML; Rowe PB; Reddel RR; Dalla-Pozza L; Symonds G
Cell Growth Differ; 1992 Nov; 3(11):839-46. PubMed ID: 1467311
[TBL] [Abstract][Full Text] [Related]
14. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies.
Avigad S; Barel D; Blau O; Malka A; Zoldan M; Mor C; Fogel M; Cohen IJ; Stark B; Goshen Y; Stein J; Zaizov R
Oncogene; 1997 Apr; 14(13):1541-5. PubMed ID: 9129144
[TBL] [Abstract][Full Text] [Related]
15. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
16. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
17. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
18. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
19. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
20. Absence of significant germ line p53 mutations in ovarian cancer patients.
Buller RE; Skilling JS; Kaliszewski S; Niemann T; Anderson B
Gynecol Oncol; 1995 Sep; 58(3):368-74. PubMed ID: 7672703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]